New York State Common Retirement Fund’s BioCryst Pharmaceuticals BCRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.39M | Buy |
138,657
+24,894
| +22% | +$225K | ﹤0.01% | 1609 |
|
|
2026
Q1 | $1.08M | Buy |
113,763
+13,073
| +13% | +$102K | ﹤0.01% | 1633 |
|
|
2025
Q4 | $785K | Buy |
100,690
+34,392
| +52% | +$249K | ﹤0.01% | 1796 |
|
|
2025
Q3 | $503K | Hold |
66,298
| – | – | ﹤0.01% | 1950 |
|
|
2025
Q2 | $594K | Buy |
66,298
+10,700
| +19% | +$99.6K | ﹤0.01% | 1852 |
|
|
2025
Q1 | $417K | Hold |
55,598
| – | – | ﹤0.01% | 1941 |
|
|
2024
Q4 | $418K | Hold |
55,598
| – | – | ﹤0.01% | 2001 |
|
|
2024
Q3 | $423K | Sell |
55,598
-29,700
| -35% | -$226K | ﹤0.01% | 1999 |
|
|
2024
Q2 | $527K | Buy |
85,298
+21,820
| +34% | +$120K | ﹤0.01% | 2029 |
|
|
2024
Q1 | $322K | Buy |
63,478
+4,403
| +7% | +$24.8K | ﹤0.01% | 2253 |
|
|
2023
Q4 | $354K | Sell |
59,075
-17,821
| -23% | -$103K | ﹤0.01% | 2229 |
|
|
2023
Q3 | $544K | Buy |
76,896
+14,498
| +23% | +$104K | ﹤0.01% | 2022 |
|
|
2023
Q2 | $439K | Sell |
62,398
-144,695
| -70% | -$1.16M | ﹤0.01% | 2146 |
|
|
2023
Q1 | $1.73M | Sell |
207,093
-35,872
| -15% | -$345K | ﹤0.01% | 1611 |
|
|
2022
Q4 | $2.79M | Buy |
242,965
+8,800
| +4% | +$110K | ﹤0.01% | 1464 |
|
|
2022
Q3 | $2.95M | Sell |
234,165
-1,797
| -0.8% | -$23.1K | ﹤0.01% | 1414 |
|
|
2022
Q2 | $2.5M | Sell |
235,962
-167,233
| -41% | -$1.73M | ﹤0.01% | 1545 |
|
|
2022
Q1 | $6.56M | Buy |
403,195
+208,200
| +107% | +$3.34M | 0.01% | 1163 |
|
|
2021
Q4 | $2.7M | Buy |
194,995
+26,142
| +15% | +$346K | ﹤0.01% | 1618 |
|
|
2021
Q3 | $2.43M | Sell |
168,853
-32,004
| -16% | -$505K | ﹤0.01% | 1661 |
|
|
2021
Q2 | $3.18M | Sell |
200,857
-11,093
| -5% | -$151K | ﹤0.01% | 1583 |
|
|
2021
Q1 | $2.16M | Buy |
211,950
+62,950
| +42% | +$649K | ﹤0.01% | 1732 |
|
|
2020
Q4 | $1.11M | Buy |
149,000
+15,900
| +12% | +$82K | ﹤0.01% | 2003 |
|
|
2020
Q3 | $457K | Hold |
133,100
| – | – | ﹤0.01% | 2255 |
|
|
2020
Q2 | $634K | Hold |
133,100
| – | – | ﹤0.01% | 2096 |
|
|
2020
Q1 | $266K | Hold |
133,100
| – | – | ﹤0.01% | 2326 |
|
|
2019
Q4 | $459K | Buy |
133,100
+31,300
| +31% | +$78.7K | ﹤0.01% | 2348 |
|
|
2019
Q3 | $292K | Hold |
101,800
| – | – | ﹤0.01% | 2578 |
|
|
2019
Q2 | $386K | Hold |
101,800
| – | – | ﹤0.01% | 2502 |
|
|
2019
Q1 | $829K | Hold |
101,800
| – | – | ﹤0.01% | 2060 |
|
|
2018
Q4 | $822K | Hold |
101,800
| – | – | ﹤0.01% | 2023 |
|
|
2018
Q3 | $777K | Hold |
101,800
| – | – | ﹤0.01% | 2214 |
|
|
2018
Q2 | $583K | Hold |
101,800
| – | – | ﹤0.01% | 2383 |
|
|
2018
Q1 | $486K | Hold |
101,800
| – | – | ﹤0.01% | 2363 |
|
|
2017
Q4 | $500K | Buy |
101,800
+18,000
| +21% | +$87.2K | ﹤0.01% | 2358 |
|
|
2017
Q3 | $439K | Hold |
83,800
| – | – | ﹤0.01% | 2410 |
|
|
2017
Q2 | $466K | Buy |
83,800
+14,499
| +21% | +$88.3K | ﹤0.01% | 2440 |
|
|
2017
Q1 | $582K | Buy |
69,301
+1
| +0% | +$7 | ﹤0.01% | 2318 |
|
|
2016
Q4 | $439K | Hold |
69,300
| – | – | ﹤0.01% | 2420 |
|
|
2016
Q3 | $306K | Hold |
69,300
| – | – | ﹤0.01% | 2571 |
|
|
2016
Q2 | $197K | Hold |
69,300
| – | – | ﹤0.01% | 2737 |
|
|
2016
Q1 | $196K | Hold |
69,300
| – | – | ﹤0.01% | 2685 |
|
|
2015
Q4 | $715K | Hold |
69,300
| – | – | ﹤0.01% | 2148 |
|
|
2015
Q3 | $790K | Sell |
69,300
-5,197
| -7% | -$69.4K | ﹤0.01% | 2082 |
|
|
2015
Q2 | $1.11M | Buy |
+74,497
| New | +$847K | ﹤0.01% | 2118 |
|
Other funds holding BCRX
OAM
NFT
WCM
DA
New York State Common Retirement Fund's BCRX Position: Q2 2026 in Review
New York State Common Retirement Fund increased its BioCryst Pharmaceuticals (BCRX) stake by 22% in Q2 2026, buying an estimated $225K and bringing the position to 138,657 shares worth $1.39M. The position accounts for ﹤0.01% of the portfolio, ranked #1609.
New York State Common Retirement Fund first reported a position in BCRX in Q2 2015 and has held it in 45 quarters since. The position peaked at $6.56M in Q1 2022. 91 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.
- New York State Common Retirement Fund held 138,657 shares of BioCryst Pharmaceuticals worth $1.39M as of Q2 2026.
- New York State Common Retirement Fund bought 24,894 BioCryst Pharmaceuticals shares in Q2 2026, an estimated $225K.
- BioCryst Pharmaceuticals made up ﹤0.01% of New York State Common Retirement Fund's portfolio in Q2 2026, its #1609 holding.
- New York State Common Retirement Fund first reported a position in BioCryst Pharmaceuticals in Q2 2015 and has held it in 45 quarters since.
- New York State Common Retirement Fund's BioCryst Pharmaceuticals position peaked at $6.56M in Q1 2022.
- 91 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.
Based on New York State Common Retirement Fund's 13F filing for Q2 2026, filed 29 Jul 2026.